Abrégé

Described herein are immunoassay methods for detecting and/or monitoring a cancer in a patient. In the method a biofluid sample from a patient is contacted with a monoclonal antibody that specifically binds to a C-terminal epitope of type XXVIII collagen, and the amount of binding between the monoclonal antibody and peptides in the sample is detected and determined.

Classes IPC  ?

• G01N 33/575 -
• G01N 33/57515 -
• G01N 33/5752 -
• G01N 33/57525 -
• G01N 33/57535 -

Abrégé

The present invention relates to methods of immunoassay for detecting a biomarker which is an MMP-cleaved fragment of collagen type-I and its use in detecting and/or monitoring diseases such as kidney disease and diseases of the cardiovascular system including the heart.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Produits et services

Diagnostic biomarker reagents for medical purposes; Diagnostic reagents for biomarkers for veterinary use; Cord blood for medical purposes; Umbilical cords for clinical use; Placentas For medicinal use; Placentas for clinical use; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Biomarker assays to identify disease activity; Diagnostic kits consisting of medical and veterinary diagnostic reagents and assays for use in connection with disease tracing, disease analysis and the quantification of disease activity; Diagnostic agents for medical use; Diagnostic reagents for medical use; clinical diagnostic agents; Diagnostics for veterinary purposes; Diagnostic reagents for veterinary use; Diagnostic agents For veterinary use; Clinical diagnostic reagents; Diagnostic agents and Diagnostic materials; Medical diagnostic test strips; Diagnostic preparations for medical purposes; Diagnostic preparations for medical or veterinary purposes. Design and development of the following goods: blood-based biomarkers for the identification, quantification and analysis of disease activity; Design and development of the following goods: diagnostic biomarker reagents for medical, veterinary and pharmaceutical purposes and For scientific purposes; Design and development of the following goods: biochemical and pharmaceutical assays and medical samples; Design and development of the following goods: biomarkers for individual use or combined for the tracking of tissue formation, development or tissue degradation; Pharmaceutical and scientific research relating to the following fields: biomarkers and the detection of biomarkers; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; Laboratory services relating to the following fields: clinical trials; Veterinary trials; Medical experiments; analysis of pharmacodynamic data; Analysis of data in connection with the following fields: biomarkers; Development of the following goods: Diagnostic preparations for medical and veterinary purposes; diagnostic equipment and diagnostic tests; Clinical testing services; Diagnostic testing services; Testing services relating to the following fields: tracking and measurement of biomarkers; testing samples for the presence of biomarkers; Laboratory services; Medical laboratory services; Research laboratories; Medical, pre-clinical, clinical, biological, biotechnological, veterinary and pharmaceutical research, the conducting of experiments, development and analysis; Information, advice and assistance relating to the aforementioned services.

Produits et services

Diagnostic biomarker reagents for medical purposes; Diagnostic reagents for biomarkers for veterinary use; Cord blood for medical purposes; Umbilical cords for clinical use; Placentas For medicinal use; Placentas for clinical use; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Biomarker assays to identify disease activity; Diagnostic kits consisting of medical and veterinary diagnostic reagents and assays for use in connection with disease tracing, disease analysis and the quantification of disease activity; Diagnostic agents for medical use; Diagnostic reagents for medical use; clinical diagnostic agents; Diagnostics for veterinary purposes; Diagnostic reagents for veterinary use; Diagnostic agents For veterinary use; Clinical diagnostic reagents; Diagnostic agents and Diagnostic materials; Medical diagnostic test strips; Diagnostic preparations for medical purposes; Diagnostic preparations for medical or veterinary purposes. Design and development of the following goods: blood-based biomarkers for the identification, quantification and analysis of disease activity; Design and development of the following goods: diagnostic biomarker reagents for medical, veterinary and pharmaceutical purposes and For scientific purposes; Design and development of the following goods: biochemical and pharmaceutical assays and medical samples; Design and development of the following goods: biomarkers for individual use or combined for the tracking of tissue formation, development or tissue degradation; Pharmaceutical and scientific research relating to the following fields: biomarkers and the detection of biomarkers; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; Laboratory services relating to the following fields: clinical trials; Veterinary trials; Medical experiments; analysis of pharmacodynamic data; Analysis of data in connection with the following fields: biomarkers; Development of the following goods: Diagnostic preparations for medical and veterinary purposes; diagnostic equipment and diagnostic tests; Clinical testing services; Diagnostic testing services; Testing services relating to the following fields: tracking and measurement of biomarkers; testing samples for the presence of biomarkers; Laboratory services; Medical laboratory services; Research laboratories; Medical, pre-clinical, clinical, biological, biotechnological, veterinary and pharmaceutical research, the conducting of experiments, development and analysis; Information, advice and assistance relating to the aforementioned services.

Produits et services

Diagnostic biomarker reagents for medical purposes; Diagnostic reagents for biomarkers for veterinary use; Cord blood for medical purposes; Umbilical cords for clinical use; Placentas For medicinal use; Placentas for clinical use; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Biomarker assays to identify disease activity; Diagnostic kits consisting of medical and veterinary diagnostic reagents and assays for use in connection with disease tracing, disease analysis and the quantification of disease activity; Diagnostic agents for medical use; Diagnostic reagents for medical use; clinical diagnostic agents; Diagnostics for veterinary purposes; Diagnostic reagents for veterinary use; Diagnostic agents For veterinary use; Clinical diagnostic reagents; Diagnostic agents and Diagnostic materials; Medical diagnostic test strips; Diagnostic preparations for medical purposes; Diagnostic preparations for medical or veterinary purposes. Design and development of the following goods: blood-based biomarkers for the identification, quantification and analysis of disease activity; Design and development of the following goods: diagnostic biomarker reagents for medical, veterinary and pharmaceutical purposes and For scientific purposes; Design and development of the following goods: biochemical and pharmaceutical assays and medical samples; Design and development of the following goods: biomarkers for individual use or combined for the tracking of tissue formation, development or tissue degradation; Pharmaceutical and scientific research relating to the following fields: biomarkers and the detection of biomarkers; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; Laboratory services relating to the following fields: clinical trials; Veterinary trials; Medical experiments; analysis of pharmacodynamic data; Analysis of data in connection with the following fields: biomarkers; Development of the following goods: Diagnostic preparations for medical and veterinary purposes; diagnostic equipment and diagnostic tests; Clinical testing services; Diagnostic testing services; Testing services relating to the following fields: tracking and measurement of biomarkers; testing samples for the presence of biomarkers; Laboratory services; Medical laboratory services; Research laboratories; Medical, pre-clinical, clinical, biological, biotechnological, veterinary and pharmaceutical research, the conducting of experiments, development and analysis; Information, advice and assistance relating to the aforementioned services.

Abrégé

The present invention relates to monoclonal antibodies that target collagen type XIX and to the sequences of the complementarity-determining regions distinguishing the monoclonal antibodies. Also, the present invention relates to immunoassays and to kits employing the antibodies. The assays of the invention are used in the diagnosis and monitoring of cancer.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to methods of immunoassay for detecting a canstatin biomarker and its use in detecting and/or monitoring diseases such as diseases of the central nervous system, lungs, and cardiovascular system including the heart.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Produits et services

Diagnostic biomarker reagents for medical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; diagnostic agents for medical use; diagnostic reagents for medical use; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations for medical purposes, diagnostic substances and diagnostic materials; medical diagnostic test strips; diagnostic preparations for medical purposes. Design and development of the following goods: blood-based biomarkers for the identification, quantification and analysis of disease activity; design and development of the following goods: diagnostic biomarker reagents for medical purposes, for pharmaceutical purposes and for scientific purposes; design and development of the following goods: biochemical and pharmaceutical assays and medical samples; design and development of the following goods: biomarkers for individual use or combined for the tracking of tissue formation, development or tissue degradation; pharmaceutical and scientific research relating to the following fields: biomarkers and the detection of biomarkers; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to the following fields: clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data in connection with the following fields: biomarkers; development of the following goods: diagnostic preparations for medical purposes, diagnostic equipment and diagnostic tests; clinical testing services; diagnostic testing services; testing services relating to the following fields: tracking and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratories; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; information, advice and assistance relating to the aforementioned services.

Abrégé

Disclosed herein are methods of immunoassay for detecting in a patient sample (such as for example a blood, serum or plasma sample) a biomarker (PRO-C12) originating from Type XII Collagen. Said methods may be used for detecting and/or monitoring cancer or a level of severity thereof. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to methods of immunoassay for detecting or monitoring inflammatory bowel disease or a severity thereof in a patient. In certain embodiments, the inflammatory bowel disease may be ulcerative colitis.

Classes IPC  ?

• G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

The present invention relates to immunoassays for detecting the whole endotrophin peptide. The assay can be used to detect and/or monitor a disease in a patient and/or assessing the likelihood of, or the severity of a disease in a patient. The disease may be selected from cardiovascular disease, idiopathic pulmonary fibrosis (IPF) or chronic kidney disease. The cardiovascular disease may in particular be heart failure, and especially heart failure with preserved ejection fraction. The immunoassay may be for assessing the likelihood of adverse outcomes of the cardiovascular disease, chronic kidney disease and all cause mortality.

Classes IPC  ?

• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Produits et services

(1) Diagnostic biomarker reagents for medical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; diagnostic agents for medical use; diagnostic reagents for medical use; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations for medical purposes, diagnostic substances and diagnostic materials; medical diagnostic test strips; diagnostic preparations for medical purposes. (1) Design and development of the following goods: blood-based biomarkers for the identification, quantification and analysis of disease activity; design and development of the following goods: diagnostic biomarker reagents for medical purposes, for pharmaceutical purposes and for scientific purposes; design and development of the following goods: biochemical and pharmaceutical assays and medical samples; design and development of the following goods: biomarkers for individual use or combined for the tracking of tissue formation, development or tissue degradation; pharmaceutical and scientific research relating to the following fields: biomarkers and the detection of biomarkers; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to the following fields: clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data in connection with the following fields: biomarkers; development of the following goods: diagnostic preparations for medical purposes, diagnostic equipment and diagnostic tests; clinical testing services; diagnostic testing services; testing services relating to the following fields: tracking and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratories; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; information, advice and assistance relating to the aforementioned services.

Produits et services

Diagnostic biomarker reagents for medical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; diagnostic agents for medical use; diagnostic reagents for medical use; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations for medical purposes, diagnostic substances and diagnostic materials; medical diagnostic test strips; diagnostic preparations for medical purposes. Design and development of the following goods: blood-based biomarkers for the identification, quantification and analysis of disease activity; design and development of the following goods: diagnostic biomarker reagents for medical purposes, for pharmaceutical purposes and for scientific purposes; design and development of the following goods: biochemical and pharmaceutical assays and medical samples; design and development of the following goods: biomarkers for individual use or combined for the tracking of tissue formation, development or tissue degradation; pharmaceutical and scientific research relating to the following fields: biomarkers and the detection of biomarkers; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to the following fields: clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data in connection with the following fields: biomarkers; development of the following goods: diagnostic preparations for medical purposes, diagnostic equipment and diagnostic tests; clinical testing services; diagnostic testing services; testing services relating to the following fields: tracking and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratories; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; information, advice and assistance relating to the aforementioned services.

Abrégé

The present invention relates to a competitive immunoassay for detecting anastellin in a biological sample, and its use in identifying patients with conditions associated with idiopathic pulmonary fibrosis (IPF). The invention also relates to a kit for performing the competitive immunoassay.

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Abrégé

Disclosed herein are methods of immunoassay for detecting, in a patient sample, the third laminin-like globular domain (LG3) fragment cleaved and released from endorepellin/perlecan by bone morphogenetic protein-1 (BMP-1). Also disclosed are monoclonal antibodies and immunoassay kits for use in these methods of immunoassay, as well as the use of these methods of immunoassay for detecting and/or monitoring fibrotic kidney diseases, such as Lupus Nephritis (LN) or IgA nephropathy (IgAN), or particular levels of severity thereof.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Produits et services

Diagnostic biomarker reagents for medical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; Diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; Diagnostic agents for medical use; Diagnostic reagents for medical use; clinical diagnostic agents; Clinical diagnostic reagents; Diagnostic preparations for medical purposes, diagnostic substances and diagnostic materials; Medical diagnostic test strips; Diagnostic preparations for medical purposes. Design and development of the following goods: blood-based biomarkers for the identification, quantification and analysis of disease activity; Design and development of the following goods: diagnostic biomarker reagents for medical purposes, for pharmaceutical purposes and for scientific purposes; Design and development of the following goods: biochemical and pharmaceutical assays and medical samples; Design and development of the following goods: biomarkers for individual use or combined for the tracking of tissue formation, development or tissue degradation; Pharmaceutical and scientific research relating to the following fields: biomarkers and the detection of biomarkers; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; Laboratory services relating to the following fields: clinical trials; Clinical trials; analysis of pharmacodynamic data; Analysis of data in connection with the following fields: biomarkers; Development of the following goods: diagnostic preparations for medical purposes, diagnostic equipment and diagnostic tests; Clinical testing services; Diagnostic testing services; Testing services relating to the following fields: tracking and measurement of biomarkers; testing samples for the presence of biomarkers; Laboratory services; Medical laboratory services; Research laboratories; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; Information, advice and assistance relating to the aforementioned services.

Abrégé

The present invention relates to immunoassays, in particular immunoassays for detecting and/or monitoring cancer in a patient, and to monoclonal antibodies and immunoassay kits for use in carrying out the immunoassays.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Described herein are monoclonal antibodies, assay kits and immumoassay methods for quantifying anastellin fragments with a N-terminus amino acid sequence PIQWNAPQPS (SEQ ID NO: 1) in a patient biofluid sample, and uses thereof for detecting and/or monitoring fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Abrégé

Provided herein are monoclonal antibodies, assay kits and immunoassay methods for quantifying anastellin fragments with a N-terminus amino acid sequence PIQWNAPQPS (SEQ ID NO: 1) in a patient biofluid sample. Also provided are methods for detecting and/or for monitoring fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) using the monoclonal antibodies.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Abrégé

Described herein are methods of immunoassay for detecting and/or monitoring cancer in a patient. A sample from the patient is contacted with denatured type III collagen. The amount of binding between the denatured type III collagen and antibodies in the sample that specifically recognise and bind to denatured type III collagen is then detected and determined, and the amount of binding is correlated with values associated with normal healthy subjects, and/or with values associated with known disease severity, and/or with values obtained from the patient at a previous time point, and/or with a predetermined cut-off value.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A method of immunoassay for detecting in a biological sample a fragment of collagen type VII alpha 1 comprising an N- or C-terminal neo-epitope, the method comprising contacting the biological sample comprising the fragment of collagen type VII alpha 1 comprising the N- or C-terminal neo-epitope with an antibody of the invention, and determining the amount of binding of the antibody

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes

Abrégé

The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Described herein are immunoassays for detecting and/or monitoring cancer in a patient, comprising contacting a sample from a patient with a monoclonal antibody that specifically binds to a C-terminus amino acid sequence that corresponds to the C-terminus of type XX collagen. Also described are said monoclonal antibodies and immunoassay kits for use in carrying out said immunoassays.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Produits et services

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations, substances and materials; medical diagnostic test strips; diagnostic preparations for medical purposes; diagnostic agents for medical use. Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; advice, information and assistance relating to the foregoing.

Abrégé

Described herein is a method of immunoassay (the "PRO-C17 assay") for measuring the levels of type XVII collagen ectodomain present in a patient sample, which method of immunoassay can be used for detecting and/or monitoring cancer and/or assessing the severity thereof in a patient. Also described are monoclonal antibodies and assay kits suitable for use in carrying out said methods.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Disclosed herein are methods of immunoassay for detecting a fibroblast activation protein (FAP) generated fragment of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring cancer or arthritis or a particular level of severity thereof in a patient. Also described are monoclonal antibodies and assay kits for use in said methods of immunoassay.

Classes IPC  ?

• C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• C07K 5/00 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• G01N 33/542 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide avec inhibition stérique ou modification du signal, p. ex. extinction de fluorescence
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of club cell secretory protein 16 (CC16) in a patient sample, which methods can be used for detecting and/or monitoring chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Produits et services

(1) Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually and in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents to detect tissue formation, tissue remodeling, or tissue destruction and to identify disease activity; medical diagnostic reagents; clinical diagnostic agents to detect tissue formation, tissue remodeling, or tissue destruction and to identify disease activity; clinical diagnostic reagents; diagnostic preparations, substances and materials to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; medical diagnostic test strips to detect tissue formation, tissue remodeling, or tissue destruction and to identify disease activity; diagnostic preparations for medical purposes to detect tissue formation, tissue remodeling, or tissue destruction and to identify disease activity; diagnostic agents for medical use to detect tissue formation, tissue remodeling, or tissue destruction and to identify disease activity. (1) Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifying patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of biomarker data to detect tissue formation, tissue remodeling, or tissue destruction and to identify disease activity; development of diagnostic preparations, equipment and tests to detect tissue formation, tissue remodeling, or tissue destruction and to identify disease activity; clinical testing services to detect tissue formation, tissue remodeling, or tissue destruction and to identify disease activity; diagnostic testing services to detect tissue formation, tissue remodeling, or tissue destruction and to identify disease activity; testing services relating to the detection and measurement of biomarkers to detect tissue formation, tissue remodeling, or tissue destruction and to identify disease activity; testing samples for the presence of biomarkers to detect tissue formation, tissue remodeling, or tissue destruction and to identify disease activity; laboratory services namely laboratory testing of materials; medical research laboratory services; research laboratory services; medical, and pharmaceutical research, experimentation, development, and analysis; pre-clinical trials, clinical trials, and biological and biotechnological research to detect tissue formation, tissue remodeling, or tissue destruction and to identify disease activity; advice, information and assistance relating to the foregoing.

Abrégé

Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

Disclosed herein are methods of immunoassay for detecting and/or monitoring a cancer in a patient, which methods comprise measuring the levels of the N-terminus amino acid sequence TAALGDIMGH ( SEQ ID NO : 1 ) ("PRO-C5" ) of the cleaved C-terminal propeptide of the «2 chain of type V collagen in a patient sample.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention relates to monoclonal antibodies that target collagen type XIX, and to immunoassays and kits employing the antibodies. The assays of the invention can be used in the diagnosis and monitoring of cancer.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to methods of immunoassay suitable for detecting and/or monitoring a cancer in a patient, immunoassay kits suitable for carrying out said methods and antibodies suitable for use in said methods and kits.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

A method of immunoassay for detecting and/or monitoring esophageal fibrosis and/or dysphagia in a patient and/or assessing the likelihood of or the severity of esophageal fibrosis and/or dysphagia in a patient by contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of the C5 domain of the α3 chain of type VI collagen.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Produits et services

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations, substances and materials; medical diagnostic test strips; diagnostic preparations for medical purposes; diagnostic agents for medical use. Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis for medical and pharmaceutical research services; advice, information and assistance relating to the foregoing.

Abrégé

Described herein are monoclonal antibodies that bind to an N- terminus sequence (SLNPDTGLWE (SEQ ID NO: 1), also referred to herein as "CILP-M") of cartilage intermediate layer protein-1 that is generated by cleavage by MMP-1, MMP-8, and MMP-12. Also disclosed are immunoassay methods and kits for detecting CILP-M in a patient sample, which methods and kits may be used for detecting and monitoring joint diseases and assessing the likelihood patient response to drug treatment.

Classes IPC  ?

• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Produits et services

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; Diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; Diagnostic preparations, substances and materials; Medical diagnostic test strips; Diagnostic preparations for medical purposes; Diagnostic agents for medical use. Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; Design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; Design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; Laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; Advice, information and assistance relating to the foregoing.

Abrégé

Disclosed herein are monoclonal antibodies that specifically recognise and bind to a C-terminus of a peptide that is the C-terminus neo-epitope formed on cleavage of the N-terminal pro-peptide of the α1-chain of type XI collagen at A′511↓, and immunoassay methods and kits using and containing the antibodies. The immunoassay methods may be used for detecting and/or monitoring and/or assessing the severity or prognosis of diseases, such as, but not limited to, cancer.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Disclosed herein are methods of immunoassay for detecting and/or monitoring a skin disease in a patient and/or determining the severity of a skin disease in a patient. The methods comprise detecting and quantifying the levels of a biomarker, comprising an N-terminus sequence of collagen type VI alpha-6, in a blood- based sample, such as whole blood, plasma or serum, from the patient. Also disclosed are antibodies suitable for use in said methods and immunoassay kits suitable for carrying out said methods.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

Described herein are monoclonal antibodies, assay kits and immumoassay methods for quantifying elastin fragments with a C-terminus amino acid sequence LPGGYGLPYT (SEQ ID NO: 1) in a patient biofluid sample, and uses thereof for detecting or quantifying fibrotic diseases such as chronic obstructive lung disease (COPD).

Classes IPC  ?

• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Abrégé

The present invention relates to a sandwich immunoassay for detecting in a biological sample cross-linked Collagen Type V, and its use in identifying patients with conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing the sandwich immunoassay.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Produits et services

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations, substances and materials; medical diagnostic test strips; diagnostic preparations for medical purposes; diagnostic agents for medical use. Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis for medical and pharmaceutical research services; advice, information and assistance relating to the foregoing.

Abrégé

The present invention relates to a sandwich immunoassay and kits for detecting in a biological sample cross-linked CTX-III, and its use in evaluating the efficacy of drugs targeting lysyl oxidases (LOXs). Cross-linked CTX-III can be used as a biomarker in diseases associated with fibrosis, including liver fibrosis, chronic intestinal disease, eosinophilic esophagitis and cancer.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

Described herein are immunoassay methods for detecting and/or monitoring a cancer in a patient by contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of type XXVIII collagen, and detecting and determining the amount of binding between the monoclonal antibody and peptides in the sample.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention relates to an antibody, wherein the antibody is specifically reactive with short isoform collagen type XVIII, but does not react with intermediate isoform collagen type XVIII or with long isoform collagen type XVIII. The invention also relates to the use of the antibody in a method of immunoassay for detecting or quantitating short isoform collagen type XVIII, wherein the method may be used to evaluate haemophilic disease.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Produits et services

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations, substances and materials; medical diagnostic test strips; diagnostic preparations for medical purposes; diagnostic agents for medical use. Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; advice, information and assistance relating to the foregoing.

Produits et services

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; Diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; Diagnostic preparations, substances and materials; Medical diagnostic test strips; Diagnostic preparations for medical purposes; Diagnostic agents for medical use. Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; Design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; Design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; Laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; Advice, information and assistance relating to the foregoing.

Produits et services

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; Diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; Diagnostic preparations, substances and materials; Medical diagnostic test strips; Diagnostic preparations for medical purposes; Diagnostic agents for medical use. Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; Design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; Design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; Laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; Advice, information and assistance relating to the foregoing.

Produits et services

(1) Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; development of diagnostic preparations, equipment and tests; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical development for medical and pharmaceutical research services; advice, information and assistance relating to the foregoing.

Produits et services

Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; medical and scientific research, namely, identifying patients for clinical trials most likely to respond to a given treatment using biomarkers; development services in the field of diagnostic preparations, equipment and tests; advice, information and assistance relating to the foregoing

Produits et services

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations, substances and materials; medical diagnostic test strips; diagnostic preparations for medical purposes; diagnostic agents for medical use. Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; advice, information and assistance relating to the foregoing.

Abrégé

The present invention relates to a type XVI collagen assay and its use in evaluating diseases associated with type XVI collagen, in particular colorectal cancer and ulcerative colitis, and for identifying a subgroup of patients with Crohn’s disease that have (or are likely to develop) fibrostenotic strictures.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

Disclosed herein are immunoassays, in particular immunoassays for detecting and/or monitoring cardiovascular disease, such as heart failure. Also disclosed are monoclonal antibodies and kits for use in said assays. The assays, antibodies and kits target a C-terminal epitope of type XXVIII collagen.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Produits et services

Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; Design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; Design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; development of diagnostic preparations, equipment and tests; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical development; Advice, information and assistance relating to the foregoing.

Abrégé

The present invention relates to a method for detecting and/or monitoring Covid-19 in a patient and/or assessing the severity and/or prognosis of Covid-19 in a patient by sandwich immunoassay.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Produits et services

diagnostic biomarker reagents for medical and clinical purposes; diagnostic biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; diagnostic biomarker assays to identify disease activity; medical diagnostic biomarker assays to quantify disease activity; medical diagnostic biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; medical diagnostic test strips for research and diagnostic use for protein fragment detection, disease detection, disease analysis and quantifying disease activity; diagnostic preparations for medical purposes; diagnostic agents for medical use custom design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; custom design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; custom design and development of biochemical, pharmaceutical, and medical assays; custom design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; providing scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; medical and scientific research, namely, identification of predictive and prognostic biomarkers for clinical trials; medical and scientific research, namely, identifying patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services for clinical trials; scientific research in the nature of conducting clinical trials for others; biological research and analysis, namely, analysis of pharmacodynamic data; biological research and analysis, namely, analysis of data relating to biomarkers; development services in the field of diagnostic preparations, equipment and tests; medical and scientific research, namely, conducting clinical testing services for others; providing reagent sample testing and diagnostic services for others for scientific research purposes namely diagnostic testing services; medical research laboratory services; research laboratory services in the fields of medical and pharmaceutical research; advice, information and assistance relating to the foregoing

Produits et services

diagnostic biomarker reagents for medical and clinical purposes; diagnostic biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; diagnostic biomarker assays to identify disease activity; medical diagnostic biomarker assays to quantify disease activity; medical diagnostic biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; medical diagnostic test strips for research and diagnostic use for protein fragment detection, disease detection, disease analysis and quantifying disease activity; diagnostic preparations for medical purposes; diagnostic agents for medical use custom design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; custom design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; custom design and development of biochemical, pharmaceutical, and medical assays; custom design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; providing scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; medical and scientific research, namely, identification of predictive and prognostic biomarkers for clinical trials; medical and scientific research, namely, identifying patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services for clinical trials; scientific research in the nature of conducting clinical trials for others; biological research and analysis, namely, analysis of pharmacodynamic data; biological research and analysis, namely, analysis of data relating to biomarkers; development services in the field of diagnostic preparations, equipment and tests; medical and scientific research, namely, conducting clinical testing services for others; providing reagent sample testing and diagnostic services for others for scientific research purposes namely diagnostic testing services; medical research laboratory services; research laboratory services in the fields of medical and pharmaceutical research; advice, information and assistance relating to the foregoing

Produits et services

diagnostic biomarker reagents for medical and clinical purposes; diagnostic biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; diagnostic biomarker assays to identify disease activity; medical diagnostic biomarker assays to quantify disease activity; medical diagnostic biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; medical diagnostic test strips for research and diagnostic use for protein fragment detection, disease detection, disease analysis and quantifying disease activity; diagnostic preparations for medical purposes; diagnostic agents for medical use custom design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; custom design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; custom design and development of biochemical, pharmaceutical, and medical assays; custom design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; providing scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; medical and scientific research, namely, identification of predictive and prognostic biomarkers for clinical trials; medical and scientific research, namely, identifying patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services for clinical trials; scientific research in the nature of conducting clinical trials for others; biological research and analysis, namely, analysis of pharmacodynamic data; biological research and analysis, namely, analysis of data relating to biomarkers; development services in the field of diagnostic preparations, equipment and tests; medical and scientific research, namely, conducting clinical testing services for others; providing reagent sample testing and diagnostic services for others for scientific research purposes namely diagnostic testing services; medical research laboratory services; research laboratory services in the fields of medical and pharmaceutical research; advice, information and assistance relating to the foregoing

Produits et services

diagnostic biomarker reagents for medical and clinical purposes; diagnostic biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; diagnostic biomarker assays to identify disease activity; medical diagnostic biomarker assays to quantify disease activity; medical diagnostic biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; medical diagnostic test strips for research and diagnostic use for protein fragment detection, disease detection, disease analysis and quantifying disease activity; diagnostic preparations for medical purposes; diagnostic agents for medical use custom design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; custom design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; custom design and development of biochemical, pharmaceutical, and medical assays; custom design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; providing scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; medical and scientific research, namely, identification of predictive and prognostic biomarkers for clinical trials; medical and scientific research, namely, identifying patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services for clinical trials; scientific research in the nature of conducting clinical trials for others; biological research and analysis, namely, analysis of pharmacodynamic data; biological research and analysis, namely, analysis of data relating to biomarkers; development services in the field of diagnostic preparations, equipment and tests; medical and scientific research, namely, conducting clinical testing services for others; providing reagent sample testing and diagnostic services for others for scientific research purposes namely diagnostic testing services; medical research laboratory services; research laboratory services in the fields of medical and pharmaceutical research; advice, information and assistance relating to the foregoing

Abrégé

Disclosed herein are immunoassay methods for detecting and quantifying human neutrophil elastase (HNE) generated fragments of calprotectin in a biofluid sample; and monoclonal antibodies and assay kits for use in such methods. The methods may be used for detecting, monitoring and/or determining the status or severity of a disease characterized by or exhibiting inflammation in a patient.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

The present invention relates to an assay for detecting secreted proteome acidic and rich in cysteine (SPARC), and more specifically to its use in evaluating lung cancer.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C07K 16/46 - Immunoglobulines hybrides
• G01N 33/534 - Production de composés immunochimiques marqués avec un marqueur radioactif
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
• G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes

Abrégé

The present invention relates to immunoassays, in particular immunoassays for detecting and/or monitoring cancer in a patient, and to monoclonal antibodies and immunoassay kits for use in carrying out said immunoassays.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux

Abrégé

Described herein are methods of immunoassay for detecting and/or monitoring cancer in a patient. A sample from the patient is contacted with denatured type III collagen. The amount of binding between said denatured type III collagen and antibodies in the sample that specifically recognise and bind to denatured type III collagen is then detected and determined, and said amount of binding is correlated with values associated with normal healthy subjects, and/or with values associated with known disease severity, and/or with values obtained from said patient at a previous time point, and/or with a predetermined cut-off value.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to an assay for detecting Tumstatin, and its use in evaluating lung cancers, such as non-small cell lung cancer (NSCLC), chronic kidney disease (CKD), such as CKD resulting from diabetes, lupus nephritis (LN) and systemic lupus erythematosus (SLE).

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes

Abrégé

An assay measuring protease mediated degradation of type IV collagen and its biomarker potential for identifying cancer patients with a T-cell permissive tumor microenvironment is described.

Classes IPC  ?

• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• G01N 33/534 - Production de composés immunochimiques marqués avec un marqueur radioactif
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Produits et services

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; Diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; Diagnostic preparations, substances and materials; Medical diagnostic test strips; Diagnostic preparations for medical purposes; Diagnostic agents for medical use. Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; Design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; Design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; Laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; Advice, information and assistance relating to the foregoing.

Produits et services

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; Diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; Diagnostic preparations, substances and materials; Medical diagnostic test strips; Diagnostic preparations for medical purposes; Diagnostic agents for medical use. Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; Design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; Design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; Laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; Advice, information and assistance relating to the foregoing.

Produits et services

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; Diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; Diagnostic preparations, substances and materials; Medical diagnostic test strips; Diagnostic preparations for medical purposes; Diagnostic agents for medical use. Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; Design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; Design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; Laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; Advice, information and assistance relating to the foregoing.

Produits et services

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; Diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; Diagnostic preparations, substances and materials; Medical diagnostic test strips; Diagnostic preparations for medical purposes; Diagnostic agents for medical use. Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; Design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; Design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; Scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; Laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; Advice, information and assistance relating to the foregoing.

Abrégé

Described herein are immunoassays for detecting and/or monitoring cancer in a patient, comprising contacting a sample from a patient with a monoclonal antibody that specifically binds to a C-terminus amino acid sequence that corresponds to the C-terminus of type XX collagen. Also described are said monoclonal antibodies and immunoassay kits for use in carrying out said immunoassays.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

A method of immunoassay for detecting and/or monitoring a cardiovascular disease in a patient and/or assessing the likelihood of or the severity of a cardiovascular disease in a patient, comprising contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of the C5 domain of the α3 chain of type VI collagen, and/or contacting a biofluid sample from the patient with a monoclonal antibody that specifically binds to a C-terminal neo-epitope of the N-terminal propeptide of type III collagen.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A method of immunoassay for detecting and/or monitoring esophageal fibrosis and/or dysphagia in a patient and/or assessing the likelihood of or the severity of esophageal fibrosis and/or dysphagia in a patient, comprising contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of the C5 domain of the α3 chain of type VI collagen.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention provides monoclonal antibodies that target collagen type XXIII, and to immunoassays and kits employing the antibodies for detecting and quantifying the epitope. The invention also provides a method for identifying and monitoring subjects with inflammatory bowel disease.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Disclosed herein are monoclonal antibodies that specifically recognise and binds to a C-terminus of a peptide comprising the C-terminus neo-epitope formed on cleavage of the N- terminal pro-peptide of the α1-chain of type XI collagen at A'511↓, and immunoassay methods and kits using and comprising said antibodies. The immunoassay methods may be used for detecting and/or monitoring and/or assessing the severity or prognosis of diseases, such as but not limited to cancer.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention provides an immunological binding partner specifically reactive with a C-terminal epitope of the α1 chain of collagen Type VIII or with an N-terminal epitope of the mature form of the α1 chain of collagen Type VIII, and a method of immunoassay for detecting or quantitating in a sample the C-terminal epitope or the N-terminal epitope of the mature α1 chain of collagen type VIII.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

The present invention provides methods of immunoassays and immunoassay kits employing antibodies that specifically bind to the long and/or intermediate isoforms of type XVIII collagen. The invention also provides methods for assessing the likelihood of the patient responding to treatment with an antifibrotic drug and monitoring liver fibrosis in a patient.

Classes IPC  ?

• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/576 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour l'hépatite

Abrégé

2N-GIATKGLNGP, and its use in an immunoassay for evaluating a disease associated with collagen type X alpha 1, such as osteoarthritis.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C12N 5/16 - Cellules animales
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Abrégé

Described herein are immunoassay methods for detecting and/or monitoring a cancer in a patient, comprising contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of type XXVIII collagen, and detecting and determining the amount of binding between said monoclonal antibody and peptides in the sample.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Disclosed herein are immunoassay methods for detecting and quantifying human neutrophil elastase (HNE) generated fragments of calprotectin in a biofluid sample; and monoclonal antibodies and assay kits for use in such methods. The methods may be used for detecting, monitoring and/or determining the status or severity of a disease characterized by or exhibiting inflammation in a patient.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a sandwich immunoassay and kits for detecting in a biological sample cross-linked CTX-III, and its use in evaluating the efficacy of drugs targeting lysyl oxidases (LOXs). Cross-linked CTX-III can be used as a biomarker in diseases associated with fibrosis, including liver fibrosis, chronic intestinal disease, eosinophilic esophagitis and cancer.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present invention relates to monoclonal antibodies that target collagen type XIX, and to immunoassays and kits employing said antibodies. The assays of the invention can be used in the diagnosis and monitoring of cancer.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

A method of immunoassay for detecting in a biological sample a fragment of collagen type VII alpha 1 comprising an N- or C-terminal neo-epitope, the method comprising contacting the biological sample comprising the fragment of collagen type VII alpha 1 comprising the N- or C-terminal neo-epitope with an antibody of the invention, and determining the amount of binding of the antibody

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes

Abrégé

An assay measuring protease mediated degradation of type IV collagen and its biomarker potential for identifying cancer patients with a T-cell permissive tumor microenvironment is described.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux

Abrégé

Disclosed herein are immunoassays, in particular immunoassays for detecting and/or monitoring cardiovascular disease, such as heart failure. Also disclosed are monoclonal antibodies and kits for use in said assays. The assays, antibodies and kits target a C-terminal epitope of type XXVIII collagen.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

A method of immunoassay for detecting and/or monitoring a cardiovascular disease in a patient and/or assessing the likelihood of or the severity of a cardiovascular disease in a patient, comprising contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of the C5 domain of the a3 chain of type VI collagen, and/or contacting a biofluid sample from the patient with a monoclonal antibody that specifically binds to a C-terminal neo-epitope of the N-terminal propeptide of type III collagen.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]

Abrégé

The present invention provides monoclonal antibodies that target collagen type XXIII, and to immunoassays and kits employing said antibodies for detecting and quantifying the epitope. The invention also provides a method for identifying and monitoring subjects with inflammatory bowel disease.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes

Abrégé

An antibody specifically reactive with an epitope of collagen type X alpha 1 comprised in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1), and a method of immunoassay for detecting in a biological sample an epitope in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1) of collagen type X alpha 1, by contacting the biological sample with the antibody, and determining the amount of binding of the antibody.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

The present invention relates to a monoclonal antibody targeting a cleaved N-terminal fragment of a pro-collagen of type XI collagen, to an immunoassay, in particular a competitive immunoassay, for detecting and quantifying this cleaved N-terminal fragment in a human biofluid sample, and to the use of said assay for evaluating cancers, such as in particular non-small cell lung cancer (NSCLC).

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Provided herein are methods of selecting subjects having cancer for combination therapy that includes administering an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme. Combination therapies can include, in addition to the anti-hyaluronan agent, a tumor-targeted taxane and, optionally, a chemotherapeutic agent such as a nucleoside analog. Combinations for performing the methods are provided, as are uses of the combinations for selecting subjects for treatment. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Described herein are monoclonal antibodies, assay kits and immumoassay methods for quantifying elastin fragments having a C-terminus amino acid sequence LPGGYGLPYT (SEQ ID NO: 1) in a patient biofluid sample, and uses thereof for detecting or quantifying fibrotic diseases such as chronic obstructive lung disease (COPD).

Classes IPC  ?

• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to an assay for detecting secreted proteome acidic and rich in cysteine (SPARC), and more specifically to its use in evaluating lung cancer.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

The present invention relates to an assay for detecting Tumstatin, and its use in evaluating lung cancers, such as non-small cell lung cancer (NSCLC), chronic kidney disease (CKD), such as CKD resulting from diabetes, lupus nephritis (LN) and systemic lupus erythematosus (SLE).

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention relates to a type XVI collagen assay and its use in evaluating diseases associated with type XVI collagen, in particular colorectal cancer and ulcerative colitis, and for identifying a subgroup of patients with 5 Crohn's disease that have (or are likely to develop) fibrostenotic strictures.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

22N-GIATKGLNGP, and its use in an immunoassay for evaluating a disease associated with collagen type X alpha 1, such as osteoarthritis.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes

Abrégé

The present invention relates to an antibody, wherein the antibody is specifically reactive with short isoform collagen type XVIII, but does not react with intermediate isoform collagen type XVIII or with long isoform collagen type XVIII. The invention also relates to the use of the antibody in a method of immunoassay for detecting or quantitating short isoform collagen type XVIII, wherein the method may be used to evaluate haemophilic disease.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

The present invention relates to an antibody, wherein the antibody specifically binds to the N-terminus of Lysyl Oxidase Like-2 (LOXL2), and its use in a method of immunoassay for detecting or quantitating LOXL2 in a sample. The method may be used to evaluate LOXL2-associated diseases, and may also be used to evaluate the efficacy of anti-LOXL2 therapeutics.

Classes IPC  ?

• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes

Abrégé

A method of diagnosis or of quantitation of cancer comprising obtaining a patient biofluid sample, conducting an immunoassay to measure fragments of Nidogen-1 having an N- or C-terminal neo-epitope formed by cleavage of Nidogen-1 by Cathepsin-S, said fragments being naturally present in said sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of cancer.

Classes IPC  ?

• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Provided herein is a sandwich immunoassay for detecting cross-linked PIIINP that has at least two strands of PIIINP joined together by inter-strand cross-linking each having a C-terminal neo-epitope of PIIINP that is generated by N-protease cleavage of intact type III procollagen. A biological sample having the cross-linked PIIINP is contacted with a first surface-bound monoclonal antibody and then by a second monoclonal antibody, both specifically reactive with a neoepitope in the C-terminal sequence of PIIINP, and then binding of the second monoclonal antibody is determined. Also provided is a method for evaluating the efficacy of an antagonist drug targeting lysyl oxidases via the immunoassay and a kit containing a solid support binding the first monoclonal antibody and containing the second monoclonal antibody.

Classes IPC  ?

• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Provided herein is a sandwich immunoassay for detecting cross-linked PIIINP that has at least two strands of PIIINP joined together by inter-strand cross-linking each having a C-terminal neo-epitope of PIIINP that is generated by N-protease cleavage of intact type III procollagen. A biological sample having the cross-linked PIIINP is contacted with a first surface-bound monoclonal antibody and then by a second monoclonal antibody, both specifically reactive with a neoepitope in the C-terminal sequence of PIIINP, and then binding of the second monoclonal antibody is determined. Also provided is a method for evaluating the efficacy of an antagonist drug targeting lysyl oxidases via the immunoassay and a kit containing a solid support binding the first monoclonal antibody and containing the second monoclonal antibody.

Classes IPC  ?

• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A method of immunoassay for detecting in a biological sample a fragment of collagen type VII alpha 1 comprising an N- or C-terminal neo-epitope, the method comprising contacting the biological sample comprising the fragment of collagen type VII alpha 1 comprising the N- or C-terminal neo-epitope with an antibody of the invention, and determining the amount of binding of the antibody

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains